Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
Abstract Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic stra...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-07-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13014-020-01595-3 |
| _version_ | 1828867662075133952 |
|---|---|
| author | Lukas Käsmann Chukwuka Eze Julian Taugner Olarn Roengvoraphoj Maurice Dantes Nina-Sophie Schmidt-Hegemann Sanziana Schiopu Claus Belka Farkhad Manapov |
| author_facet | Lukas Käsmann Chukwuka Eze Julian Taugner Olarn Roengvoraphoj Maurice Dantes Nina-Sophie Schmidt-Hegemann Sanziana Schiopu Claus Belka Farkhad Manapov |
| author_sort | Lukas Käsmann |
| collection | DOAJ |
| description | Abstract Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC. |
| first_indexed | 2024-12-13T05:15:27Z |
| format | Article |
| id | doaj.art-4e9000d77273443982ebf27f139fecaf |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-12-13T05:15:27Z |
| publishDate | 2020-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-4e9000d77273443982ebf27f139fecaf2022-12-21T23:58:26ZengBMCRadiation Oncology1748-717X2020-07-0115111410.1186/s13014-020-01595-3Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategyLukas Käsmann0Chukwuka Eze1Julian Taugner2Olarn Roengvoraphoj3Maurice Dantes4Nina-Sophie Schmidt-Hegemann5Sanziana Schiopu6Claus Belka7Farkhad Manapov8Department of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichComprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL)Department of Radiation Oncology, University Hospital, LMU MunichDepartment of Radiation Oncology, University Hospital, LMU MunichAbstract Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC.http://link.springer.com/article/10.1186/s13014-020-01595-3Non-small cell lung cancerChemoradioimmunotherapyMultimodal treatmentImmunotherapy |
| spellingShingle | Lukas Käsmann Chukwuka Eze Julian Taugner Olarn Roengvoraphoj Maurice Dantes Nina-Sophie Schmidt-Hegemann Sanziana Schiopu Claus Belka Farkhad Manapov Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy Radiation Oncology Non-small cell lung cancer Chemoradioimmunotherapy Multimodal treatment Immunotherapy |
| title | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
| title_full | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
| title_fullStr | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
| title_full_unstemmed | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
| title_short | Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy |
| title_sort | chemoradioimmunotherapy of inoperable stage iii non small cell lung cancer immunological rationale and current clinical trials establishing a novel multimodal strategy |
| topic | Non-small cell lung cancer Chemoradioimmunotherapy Multimodal treatment Immunotherapy |
| url | http://link.springer.com/article/10.1186/s13014-020-01595-3 |
| work_keys_str_mv | AT lukaskasmann chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT chukwukaeze chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT juliantaugner chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT olarnroengvoraphoj chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT mauricedantes chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT ninasophieschmidthegemann chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT sanzianaschiopu chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT clausbelka chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy AT farkhadmanapov chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy |